We screened 1021 α-NP antibody pairs against three sources of SARS-CoV-2 nucleocapsid protein, and identified multiple pairs, inclusive of antibodies from several different commercially available sources, as promising candidates towards the development of lateral flow assays for the detection of SARS-CoV-2. Further work is required for the development of a point-of-care test for SARS-CoV-2, though the high-performance antibodies identified in this work may hasten its development. The antibody pairs identified as top-ranking pairs against pooled clinical samples should be interpreted as worth further testing, not necessarily a precisely ordered list of the best candidate reagents for developing an LFA. The top-ranking pairs against clinical samples have demonstrated strong affinity for (some form of) native antigen in the context of lateral flow through nitrocellulose. However, we suggest that multiple of these top antibody pairs be tested further by anyone attempting to develop an LFA using these data, as the precise interaction of all assay components, materials, and methods (especially when different from the conditions in our tests) can affect pair performance.